Shots:

• Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M.  Dova to receive upfront of $27.50/share in cash- $1.50/share on approval of Doptelet as CVR- representing a total consideration of up to $29.00/share with a premium of 36% to Dova’s closing price on Sept 27- 2019
• The focus of the acquisition is to bolster Sobi’s hematology & orphan diseases portfolio with the addition of Dova’s Doptelet and expand its presence in the US. The transaction is expected to be completed in Q4’19
• Dova’s Doptelet (avatrombopag) is a second-generation small molecule thrombopoietin receptor (TPO) agonist- act by increasing platelet count to treat thrombocytopenia- currently being evaluated in P-III study for chemotherapy-induced thrombocytopenia (CIT) and has received FDA’s approval for CLD & ITP in May’2018 & Jun’2019 respectively

Source 1- Source2 to­ read full press release/ article | Ref: Sobi- Dova Pharmaceutical | Image: Pharmaceutical Technology